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Article category: Research article, Cancer epidemiology 
 
What’s new: 
 
Social inequalities in cancer survival are significant worldwide. However, no previous study has 
investigated the influence of social environment on cancer survival for various cancers in the French 
Network of Cancer Registries. Our findings show, for the first time in France, that cancer survival was 
lower for patients living in the most deprived areas compared to those living in the least deprived 
ones, for almost all solid tumors, with variable magnitudes across the cancer sites. 
 
Abstract: 
 
Social inequalities are concerning along the cancer continuum. In France, social gradient in health is 
particularly marked but little is known about social gradient in cancer survival. We aimed to 
investigate the influence of socioeconomic environment on cancer survival, for all cancers reported 
in the French Network of Cancer Registries. We analyzed 189,657 solid tumors diagnosed between 
2006 and 2009, recorded in 18 registries. The European Deprivation Index (EDI), an ecological index 
measuring relative poverty in small geographic areas, assessed social environment. The EDI was 
categorized into quintiles of the national distribution. One- and five-year age-standardized net 
survival (ASNS) were estimated for each solid tumor site and deprivation quintile, among men and 
among women. We found that 5-year ASNS was lower among patients living in the most deprived 
areas compared to those living in the least deprived ones for 14/16 cancers among men and 16/18 
cancers among women. The extent of cancer survival disparities according to deprivation varied 
substantially across the cancer sites. The reduction in ASNS between the least and the most deprived 
quintile reached 34% for liver cancer among men and 59% for bile duct cancer among women. For 
pancreas, stomach and esophagus cancer (among men), and ovary and stomach cancer (among 
women), deprivation gaps were larger at 1-year than 5-year survival. In conclusion, survival was 
worse in the most deprived areas for almost all cancers. Our results from population-based cancer 
registries data highlight the need for implementing actions to reduce social inequalities in cancer 
survival in France. 
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Introduction 
Social inequalities along the cancer continuum are of major concern, resulting in social 
disparities in cancer survival.1-8 According to many studies, patients with a low socioeconomic status 
experienced a 30 to 50% lower cancer survival compared to those with a high socioeconomic status.1-
4  
The mechanisms explaining disparities in cancer survival according to social deprivation are 
complex and not fully understood. Underlying hypotheses have been proposed by previous research 
and comprise a more advanced stage at diagnosis, worse access to healthcare services, less 
optimized choices of treatment, as well as higher prevalence of comorbid illnesses and more 
frequent unhealthy lifestyle among the more socially disadvantaged.1-5,7,9 Individual socioeconomic 
characteristics are known to be strong predictors of cancer survival as revealed in many studies 
worldwide.10-17 However, some of the potential explanations mentioned above as well as previous 
research14,18,19 suggest that not only individual but also contextual and environmental factors might 
contribute to social inequalities in cancer survival. Indeed, several population-based studies from 
different countries have shown that patients living in the most deprived areas experienced lower 
survival rates than those living in the most affluent ones, for most of the cancer sites.14,18,20-27 
Health indicators in France are among the best in the world, especially with regard to 
cancer.28,29 Although France has a universal health coverage system, it is not free of charge and do 
not impede health inequalities. As a matter of fact, social inequalities in cancer screening,30,31 
incidence32 and mortality33 are substantial and relatively high in France considering the European 
context.34,35 Thus, one can expect social inequalities in cancer survival to be important as well. 
Tackling socio-spatial inequalities in France is therefore one of the priorities of the 2014-2019 
National Cancer Plan. However, although such data is essential to guide public health policies, little is 
known about social inequalities in cancer survival in France and specifically for each cancer site, since 
the few existing studies were restricted to a specific region, only one cancer site and/or small 
samples.36-40  
The French Network of Cancer Registries are a resourceful tool to investigate cancer survival 
because they provide a large coverage of the French population, completeness of cases in the 
considered areas, and certified high quality data. Moreover, life tables are available in France in 
order to estimate net survival (that is the probability of surviving a specific cancer in the absence of 
other causes of death)41 based on cancer registries data and in the absence of cause of death 
information. To study social deprivation and cancer survival (or incidence) in the absence of 
individual socioeconomic information available in those registries and in order to account for the 
contextual part of social environment, an ecological index of social deprivation the European 
Deprivation Index (EDI)42 has been developed in France and assigned to each cancer case in the 
cancer registries.  
Thus, the aim of the present study was to investigate, for the first time in France, the 
disparities in net survival according to the social environment (assessed by the EDI) for a wide range 
of solid tumor sites, and based on the French Network of Cancer Registries data. 
 
Materials and Methods 
Data - French Network of Cancer Registries (FRANCIM) 
The study population comprised 189,657 primary invasive solid tumors diagnosed between 1 
January 2006 and 31 December 2009, in patients over 15 years old, and recorded in 18 population-
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved.
4 
 
based cancer registries (members of the French Network of Cancer Registries (FRANCIM)). Follow-up 
ended on 30 June 2013, i.e. patients alive at that date had their survival time censored.  
The areas covered by the French Network of Cancer registries and by the registries included 
in this study are described on the map presented in supplementary figure 1. A brief description of the 
cancer registries included in the present study is provided in table 1. Each registry covered the entire 
corresponding French Département, except for the ‘Lille area cancer registry’, which encompassed 
only the city of Lille and its suburban area. The area covered by the registries included in the present 
study represented 20% of the French population and 20% of the French territory. Cancer diagnoses 
were available only from 1 January 2008 for the ‘Gironde registry of Central nervous system (CNS) 
tumors’ and the ‘Lille area cancer registry’ and from 1 January 2009 in the ‘Haute-Vienne cancer 
registry’. Quality controls of the FRANCIM registries have been regularly completed by the National 
Committee of Registries (CER) at the national level, and the International Agency for Research on 
Cancer (IARC) at the international level. The study was approved by the Consultative Committee for 
the Processing of Health Research Data (CCTIRS) and the French Data Protection Authority (CNIL). 
Information available in the registries databases were date of birth, sex, date of cancer 
diagnosis, topographical and morphological codes of the 3rd edition of the International Classification 
of Diseases for Oncology (ICD-O-3), vital status and date of last information (on vital status). The 
information on vital status was collected through an active standardized search procedure by the 
French Network of Cancer Registries, based on requests to the Repertoire National d’Identification 
des Personnes Physiques and, if necessary, other sources of information (medical records or 
birthplace public services).43 Survival time was defined as the difference between the date of last 
information and the date of cancer diagnosis. Information on the day or month of the date of last 
information was missing in 54 cases (<0.1%) (table 1). Missing days were then replaced by 15 and 
missing months by July. The date of death was the same as the date of cancer diagnosis in 222 cases 
(0.1%). Those cases were included in the analyses with a survival time equals to 0.5 day. Lost to 
follow-up accounted for 2.1% overall. Cancer sites were classified according to the ICD-0-3. Only the 
19 most common solid tumor sites were included in the study (table 2).  
 
Social Deprivation 
Social environment was assessed by the EDI, an ecological index measuring relative poverty 
in small geographic areas, based on information from the European Union Statistics on Income and 
Living Conditions survey (EU-SILC) and on census information.42 In France, the EDI has been 
developed at the ‘Ilots Regroupes pour l'Information Statistique’ (IRIS) level, the smallest geographic 
area for which data from the 2007 census were available. IRIS have been defined by the ‘Institut 
National de la Statistique et des Etudes Economiques’ (INSEE) and comprised approximately 2,000 
inhabitants. In each IRIS, the continuous value of the EDI has been calculated and categorized into 
quintiles of the EDI national distribution  ‘Quintile 1’ (Q1) being the most affluent one and ‘Quintile 
5’ (Q5) the most deprived one.  
For each cancer diagnosed in FRANCIM registries, patient’s address at the time of diagnosis, 
has been collected, geolocalized using Geographic Information Systems (ArcGIS 10.2, ESRI, Redlands, 
California, USA), and assigned to an IRIS. Hence, a deprivation quintile has been attributed to each 
cancer case recorded in the registries.  
 
Statistical analyses  
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Net survival was estimated using the consistent estimator proposed by Pohar-Perme41 for 
estimating cancer-specific survival in the absence of cause of death information (not available in 
FRANCIM registries). This method provides cancer-specific survival probabilities, which are not 
impacted by other causes of death, assuming patients could only die from their cancer. Net survival is 
based on the excess mortality hazard estimation for the studied cancer. This excess mortality is 
obtained by subtracting from the observed mortality in the registry for this cancer the expected 
mortality, as derived from general population life tables (produced by INSEE). These life table data 
contain mortality rates detailed by age, sex, year (1975 to 2017) and French Département of 
residence. Furthermore, net survival estimate relies on the assumption that the studied cancer 
represents a small part of the overall mortality.  
Net survival probabilities were age-standardized according to the International Cancer 
Survival Standards (ICSS)44 with age strata and weights depending on the cancer site. We computed 
95% confidence intervals (95% CI) of age-standardized net survival (ASNS) probabilities using 
Greenwood’s formula and the delta-method, assuming normality of the log of the cumulative excess 
hazard. When the standardization stratum included less than 10 cases, we merged adjacent age 
categories and assigned the sum of their respective weights to the combined age category to 
estimate ASNS. We could not compute standardized estimates for breast cancer survival among men 
because of the limited sample size (N=275). ASNS are survival probabilities (ranging from 0 to 1) but 
will be presented throughout the results section as percentages (ranging from 0 to 100). 
For each tumor site, 1-year and 5-year ASNS were assessed overall and for each deprivation 
quintile (separately among men and women). Then, based on these results, we calculated the 
deprivation gap (DG), that is the difference in ASNS between the least (Q1) and the most (Q5) 
deprived quintiles (DG=ASNSQ1-ASNSQ5). The 95% CI of deprivation gap was derived using the 
variance of the ASNS of the least deprived quintile (var(ASNSQ1)) and the variance of the ASNS of the 
most deprived quintile (var(ASNSQ5)), previously obtained when calculating the 95% CI of the ASNS 
probabilities. Since ASNSQ1 and ASNSQ5 were independently estimated, we used the following 
formulas to estimate the variance of the DG: Var(DG(t)) = Var(ASNSQ1(t) – ASNSQ5(t)) = 
Var(ASNSQ1(t)) + Var(ASNSQ2(t)). Then, we derived the 95% CI of the DG, assuming the DG follows 
approximately a normal distribution. We considered that the difference in ASNS between the least 
and the most deprived quintile was statistically significant when the 95% confidence interval of the 
corresponding deprivation gap did not include zero. Furthermore, the percentage of variation of 
ASNS between the least (Q1) and the most (Q5) deprived quintiles was derived (ASNSQ1→Q5=( 
ASNSQ5- ASNSQ1)/ ASNSQ1*100).  
Cases with missing values regarding the EDI (less than 1%) were excluded from the analyses 
(complete cases analyses). 
Analyses were performed using R software (version 3.3.2) and the ‘relsurv’ (2.1-2) package 
for the estimation of net survival. 
 
Results 
A total of 109,071 cancer cases allocated over 16 solid tumor sites were analyzed among 
men, and 80,586 cancer cases allocated over 18 solid tumor sites were analyzed among women 
(table 2). For all solid tumor sites and for both sexes, 5-year ASNS were comparable to the latest 
reference data relative to cancer survival in France.43  
Distribution of patients into the five quintiles of deprivation was very variable across the 
cancer sites. In particular, patients living in the most deprived quintile (Q5) were overrepresented for 
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cervical cancer, lung cancer, head & neck cancers, bladder cancer, liver cancer (among women only), 
and to a lesser extent sarcoma, stomach cancer, bile duct cancer, esophagus cancer, corpus uteri 
cancer, CNS cancer and pancreas cancer (among women only). On the opposite, patients living in the 
most affluent quintile (Q1) were overrepresented for melanoma and CNS cancer (among men only). 
Tables 3 and 4 provide 1- and 5-year ASNS in each deprivation quintile and the deprivation 
gaps (DG) for each cancer site, respectively among men and among women. One-year ASNS was 
lower among patients living in the most deprived quintile (Q5) than among patients living in the least 
deprived one (Q1) for all cancer sites except thyroid cancer among men, and except sarcoma and 
thyroid cancer among women. Among men, the deprivation gap regarding 1-year ASNS, was 
statistically significant for colon-rectum cancer (ASNSQ1= 85.6, ASNSQ5= 82.7, DG= 2.9 [1.0;4.8]), head 
and neck cancers (ASNSQ1= 75.7, ASNSQ5= 68.9, DG= 6.8 [3.1;10.5]), stomach cancer (ASNSQ1= 58.8, 
ASNSQ5= 52.4, DG= 6.4 [1.1;11.7]), bladder cancer (ASNSQ1= 81.7, ASNSQ5= 76.9, DG= 4.8 [0.8;8.7]), 
esophagus cancer (ASNSQ1= 51.1, ASNSQ5= 43.5, DG= 7.5 [1.9;13.2]), liver cancer (ASNSQ1= 49.0, 
ASNSQ5= 42.2, DG= 6.8 [2.1;11.4]) and pancreas cancer (ASNSQ1= 36.3, ASNSQ5= 29.5, DG= 6.7 
[1.7;11.8]). Among women, the deprivation gap regarding 1-year ASNS, was statistically significant 
for colon-rectum cancer (ASNSQ1= 85.9, ASNSQ5= 82.0, DG= 3.9 [1.9;6.0]), corpus uteri cancer 
(ASNSQ1= 91.8, ASNSQ5= 88.3, DG= 3.5 [0.5;6.5]), breast cancer (ASNSQ1= 97.6, ASNSQ5= 96.0, DG= 1.6 
[0.6;2.5]), bladder cancer (ASNSQ1= 77.4, ASNSQ5= 67.9, DG= 9.5 [1.3;17.8]), esophagus cancer 
(ASNSQ1= 56.4, ASNSQ5= 40.8, DG= 15.7 [3.3;28.1]) and pancreas cancer (ASNSQ1= 37.5, ASNSQ5= 30.2, 
DG= 7.2 [1.6;12.8]). 
Five-year ASNS was lower in Q5 than in Q1 for all cancer sites except sarcoma and bile duct 
cancer among men and except sarcoma and CNS cancer among women (tables 3 and 4). Among men, 
the deprivation gap regarding 5-year ASNS was statistically significant for lung cancer (ASNSQ1= 17.2, 
ASNSQ5= 14.3, DG= 2.9 [0.7;5.0]), colon-rectum cancer (ASNSQ1= 64.2, ASNSQ5= 57.9, DG= 6.4 
[3.3;9.5]), head and neck cancers (ASNSQ1= 49.7, ASNSQ5= 38.1, DG= 11.6 [6.8;16.5]), prostate cancer 
(ASNSQ1= 93.8, ASNSQ5= 90.7, DG= 3.0 [1.1;5.0]), bladder cancer (ASNSQ1= 57.7, ASNSQ5= 51.2, DG= 
6.4 [0.9;12.0]) as well as liver cancer (ASNSQ1= 18.4, ASNSQ5= 12.2, DG= 6.2 [2.5;10.0]). Among 
women, the deprivation gap regarding 5-year ASNS was statistically significant for colon-rectum 
cancer (ASNSQ1= 66.0, ASNSQ5= 60.6, DG= 5.5 [2.2;8.7]), head and neck cancers (ASNSQ1= 56.4, 
ASNSQ5= 41.6, DG= 14.9 [6.2;23.5]), breast cancer (ASNSQ1= 88.8, ASNSQ5= 83.7, DG= 5.1 [2.9;7.3]), 
cervical cancer (ASNSQ1= 68.2, ASNSQ5= 56.9, DG= 11.3 [3.4;19.3]), bile duct cancer (ASNSQ1= 23.1, 
ASNSQ5= 9.5, DG= 13.6 [4.0;23.3]) and esophagus cancer (ASNSQ1= 23.0, ASNSQ5= 10.9, DG= 12.1 
[1.9;22.4]).  
Various patterns emerged regarding fluctuation of ASNS according to deprivation quintile 
(tables 3 and 4). There was a negative gradient in ASNS with increasing deprivation for example for 
prostate cancer, breast cancer, colon-rectum cancer, corpus uteri cancer. For some cancer sites such 
as ovarian cancer, head and neck cancers, lung cancer or kidney cancer, we could not observe such a 
clear relation but ASNS in the most deprived quintiles was overall lower than ASNS in the least 
deprived ones. In addition, for some cancer sites, ASNS in the most deprived quintile (Q5) was lower 
than ASNS in the least deprived one (Q1) but ASNS varied inconsistently between Q2 and Q4 (e.g. 
pancreas cancer, stomach cancer, cervical cancer). 
  Figures 1 and 2 show the variation of 1-year and 5-year ASNS between Q1 and Q5, for each 
cancer site among men and women, respectively. A decrease of at least 5% in 1-year ASNS between 
Q1 and Q5 was observed in 11/16 cancer sites among men and 8/18 cancer sites among women. The 
decline in 1-year ASNS between Q1 and Q5 reached 19% for pancreas cancer, 15% for esophagus 
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cancer, 14% for liver cancer among men and 28% for esophagus cancer, 19% for pancreas cancer, 
19% for bile duct cancer among women. Furthermore, there was a decrease of at least 5% in 5-year 
ASNS between Q1 and Q5 in 11/16 cancer sites among men and 11/18 cancer sites among women. 
The reduction in 5-year ASNS between Q1 and Q5 reached 34% for liver cancer, 23% for head and 
neck cancers, 20% for breast cancer among men and 59% for bile duct cancer, 53% for esophagus 
cancer, 29% for pancreas cancer among women.  
For most of the cancer sites, the decline in ASNS between Q1 and Q5 widened from 1 year of 
follow-up to 5 years of follow up (figures 1 and 2). However, this decline was larger at 1 year of 
follow-up than at 5 years of follow up for pancreas cancer (1-year ASNSQ1→Q5= 19% vs. 5-year 
ASNSQ1→Q5= 8%), stomach cancer (1-year ASNSQ1→Q5= 11% vs. 5-year ASNSQ1→Q5= 7%), esophagus 
cancer (1-year ASNSQ1→Q5= 15% vs. 5-year ASNSQ1→Q5= 2%) and CNS cancer (1-year ASNSQ1→Q5= 
6% vs. 5-year ASNSQ1→Q5= 3%) in men and for stomach cancer (1-year ASNSQ1→Q5= 7% vs. 5-year 
ASNSQ1→Q5= 2%) and ovary cancer (1-year ASNSQ1→Q5= 5% vs. 5-year ASNSQ1→Q5= 2%) in women. 
Supplementary analyses revealed consistent results when stratifying on the year of diagnosis, 
the French Département, the registry or the type of registry (i.e. general or specialized) (data not 
shown). 
 
Discussion 
We found that cancer survival was (or tended to be) lower among patients living in the most 
deprived areas compared to those living in the least deprived ones, for almost all cancer sites (14/16 
among men and 16/18 among women at 5 years of follow-up) while no significant inverse association 
was observed for the remaining cancer sites. The extent of the impact of social environment on 
cancer survival varied a lot across the cancer sites. The decline in ASNS between the least and the 
most deprived quintiles generally widened during follow-up, but for some cancer sites (e.g. ovary 
cancer, stomach cancer), this decline was wider at 1 year than at 5 years of follow-up. Moreover, 
patterns were different between men and women, since larger variations of survival between the 
least and the most deprived quintile were observed in women compared to men (the maximum 
variation of survival between Q1 and Q5 was 59% in women vs. 34% in men). In addition, the impact 
of social deprivation could differ between men and women for a given cancer site (e.g. significant 
difference in survival from bile duct cancer according to deprivation among women vs. no effect 
among men). 
 
 Previous studies investigating the influence of social environment on cancer survival for 
several solid tumor sites with comparable methodology (i.e. population-based registries data, 
ecological deprivation index, net survival) also showed lower survival among patients living in the 
most deprived environments compared to those living in the least deprived ones, for most cancer 
sites.18,20-25 More broadly, all studies investigating social inequalities in cancer survival worldwide 
have reported lower survival among the most deprived for a large majority of cancer sites, with no 
significant inverse association.10-17,26,27 Our findings are therefore supported by those from the 
literature, and bring new information about the situation in France and the impact of social 
deprivation on cancer survival for cancer sites with mitigated results in the literature (such as 
stomach, ovary, melanoma, thyroid, CNS or pancreas). The deprivation gaps were broadly similar to 
those reported by studies with comparable methodology, conducted in the UK,20 in Germany,22 in 
Japan,21 in Australia24 and in New Zealand.23 Compared to those previous studies, we found slightly 
smaller deprivation gaps for colon-rectum cancer, prostate cancer and esophagus cancer (in men) 
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and slightly wider deprivation gaps for esophagus cancer (in women), head and neck cancers, breast 
cancer and cervical cancer. However, differences in methodology across studies investigating the 
influence of social environment on cancer survival make it difficult to precisely compare their results. 
It would be very useful to have access to cancer registries data, with the same deprivation index 
estimated at a comparable geographical level, for all countries in Europe, to place disparities in 
cancer survival according to the social environment observed in France with regard to the European 
context.  
 The lower survival found among patients living in the most deprived areas compared to those 
living in the least deprived ones regarding colon-rectum cancer, breast cancer and cervical cancer 
might result from inequalities in cancer screening uptake,1-4,7 which have been identified in several 
French studies.30,31,45 Additionally, disparities in stage at diagnosis and therapeutic management 
according to deprivation have been related to cancer survival inequalities in previous research.1-
4,7,11,12,15,16,26,27,46 However, neither stage at diagnosis nor patients’ treatment history were available in 
the cancer registries data used for the present study. Collection of data on stage at cancer diagnosis 
by the French network of cancer registries has been initiated in a pilot study for breast and colon-
rectum cancers diagnosed after 2009.47 It would be very much valuable to reproduce the present 
study, accounting for data on stage at cancer diagnosis, for all cancers reported in the Francim 
registries after 2009, in order to better explain the disparities in cancer survival according to social 
environment. In the present study, we found substantial variations in survival between patients living 
in the least versus the most deprived environment regarding lung cancer, head and neck cancers or 
digestive cancers, whose incidence and survival are (independently) strongly related to behavioral 
risk factors (such as tobacco smoking, alcohol intake, unhealthy diet). A potential explanation to this 
may be that these risk factors are more frequent among the most socially disadvantaged, resulting in 
higher risk of cancer incidence on the one hand, and lower chances of cancer survival on the other 
hand among them.48 It would be interesting in further research to investigate whether the lower 
survival among the most deprived could be due to higher occurrence of risk factors-related cancer 
histological types among them. Some studies also suggest that the higher occurrence of risk factors 
among the most deprived might be responsible for higher comorbidities prevalence, preventing from 
using optimal cancer treatments or masking cancer symptoms and delaying its diagnosis, thus 
reducing survival among them.1-4,7,9  
Overall, our results confirm the existence of a social gradient regarding cancer survival in 
France, which is part of the ‘social gradient in health’ described by the World Health Organization.49 
Furthermore, we highlighted a different impact of social environment on cancer survival across the 
cancer sites, according to the time of follow-up or between men and women, suggesting different 
underlying mechanisms and the need for implementing specific actions to reduce social inequalities 
in cancer survival in each situation.  
The social gradient in cancer survival observed in the present study widened between one 
year and five years of follow-up for a majority of the cancer sites, except pancreas cancer, stomach 
cancer, esophagus cancer and CNS cancer among men, and stomach cancer and ovary cancer among 
women. This suggests that disparities in cancer survival may not uniquely result from differences in 
stage at diagnosis or initial therapeutic management according to deprivation, but could build up 
throughout every step of the follow-up and relapse. From a methodological point of view, such 
results also point out a potential non-proportional effect of deprivation, which will be addressed (as 
well as possible non-linearity of EDI) in a next step using flexible excess-hazard regression models.50  
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A previous study,32 that used the same data from the French Network of Cancer registries 
(diagnoses 2006-2009) has investigated the influence of the EDI on cancer incidence. It is worth 
noting that, while a more deprived environment was (or tended to be) systematically associated with 
lower survival for all cancer sites in the present study, either positive or negative social gradients 
could be observed regarding cancer incidence in that previous study. As a matter of fact, Bryere et al. 
have found that individuals living in the most deprived environment experienced higher incidence 
rates for head and neck cancers, lung cancer, digestive cancers and cervical cancer but lower 
incidence rates for melanoma, prostate cancer, breast cancer and ovary cancer as compared to those 
living in the least deprived environment. It is important to better understand and distinguish the 
social gradients regarding cancer incidence and cancer survival respectively, since actions to reduce 
them must be considerably different. 
 
This is the first study, to our knowledge, that investigates disparities in cancer survival 
according to social environment for several solid tumor sites, through population-based cancer 
registries in France. The French Network of Cancer Registries represent a powerful tool to monitor 
cancer survival (and disparities in survival according to social deprivation) since they are based on 
large population-based data and offer high quality and validated data. Using net survival allowed us 
to observe cancer survival independently of mortality from other causes than the cancer of interest, 
and independently of the national general population mortality.41 Moreover, we used a validated 
indicator for social deprivation, developed and used in several European countries.51 The EDI offers 
an acceptable approximation of social deprivation at the individual level when used in small 
geographic units such as IRIS,52 while also providing information on the social environment, known to 
have a proper effect on cancer survival for some cancer sites.14,18 The measure of the variation of 
survival between the least and the most deprived quintiles brought new information on the extent of 
survival disparities according to social deprivation that can be compared across cancer sites or 
different times of follow-up since it is a relative measure of the deprivation gap. 
Our study presents some limitations. In the absence of reliable data on cause of death, we 
used life tables from INSEE to estimate expected survival. However, those life tables did not provide 
deprivation-specific expected mortality rates even though it is highly possible that the most deprived 
individuals have higher mortality in the general population. Therefore, it is likely that expected 
mortality was underestimated among the most deprived patients and that excess mortality among 
them was overestimated (and thus the deprivation gaps). It would be more accurate to estimate net 
survival based on deprivation-specific life tables but such life tables do not exist in France yet. A 
possible way to comprehend the maximal extent of the bias induced by the absence of deprivation-
specific life tables would be to use, in sensitivity analyses, those from another country with known 
substantial difference in general population mortality according to deprivation (“worst case 
scenario”). This has been done by Ito and colleagues21 who used England and Wales deprivation-
specific life tables to analyze net survival of Osaka population (Japan). The authors have shown 
(assuming similar inequalities in general population mortality in Osaka and in England and Wales) 
that overestimation of the deprivation gap was small at one-year survival but non-negligible at five-
year survival. However, sensitivity analyses using this type of modelling approach cannot fully 
compensate the absence of deprivation-specific lifetables. Building such deprivation-specific life 
tables remains a major step forward that needs to be undertaken in France for studying 
socioeconomic inequalities in cancer survival. Another important point to note is that the French 
Network of Cancer Registries used in this study do not entirely cover France but around 20% of the 
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population, preventing us from generalizing our results to the whole French population diagnosed 
with cancer. As it turns out, the area covered by the French Network of Cancer Registries comprises 
more rural zones than the whole French territory and excludes major metropolis (Paris, Marseille, 
Lyon). Therefore, the whole French population diagnosed with cancer may somewhat differ from our 
study population. However, while this might influence cancer incidence or general mortality, it is not 
sure whether it would modify the impact of deprivation on cancer survival in the whole French 
population diagnosed with cancer as compared to our study population. Moreover, data regarding 
stage at cancer diagnosis, access to healthcare services, treatment or comorbid illnesses were not 
available. Therefore, we could not investigate the influence of deprivation on cancer survival 
according to those parameters. 
 
In conclusion, this study provides reference data on disparities in cancer survival according to 
social environment, for several solid tumor sites in France, and confirms the existence of important 
and recurring social inequalities in cancer survival. These results thereby suggest that the French 
health coverage and social security system may not be sufficient to eliminate the social gradient in 
health. It would be of great interest to reproduce this study on a regular basis in order to monitor 
social inequalities in cancer survival over time, which could help public health policies implementing 
actions to reduce social deprivation-related disparities in cancer survival. In order to improve cancer 
survival among patients living in the most deprived environment, it is important to implement 
actions along the whole cancer continuum and to focus on both incidence-related (cancer screening, 
prevalence of cancer risk factors etc.) and survival-related (stage at diagnosis, access to healthcare 
services, treatment modalities etc.) factors. To that end, further research about the relative part of 
social inequalities in cancer incidence and cancer lethality in the overall cancer mortality-related 
disparities would be relevant. 
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Tables Legends 
 
Table 1. Description of records from the FRANCIM registries used in the study  
 
 
Table 2. Characteristics of the population by cancer site and by sex (FRANCIM registries, cancer cases diagnosed 
between 2006-2009) 
 
* 1- Topography codes for sarcoma: C381, C382, C383, C47, C480, C49, C696, C76, C809, morphology codes for sarcoma : 8900-05, 8910, 8912, 8920, 8991, 
8810, 8811, 8813-15, 8821, 8823, 8834-35, 8820, 8822, 8824-27, 9150, 9160, 9491, 9540-971, 9580, 9140, 8587, 8710-13, 8806, 8831-33, 8836, 8840-42, 8850-
58, 8860-62, 8870, 8880, 8881, 8890-98, 8921, 8982, 8990, 9040-44, 9120-25, 9130-33, 9135, 9136, 9141, 9142, 9161, 9170-75, 9231, 9251, 9252, 9373, 9581, 
8830, 8963, 9180, 9210, 9220, 240, 9260, 9364, 9365, 8800-05 
ASNS: age-standardized net survival 
 
 
Table 3. One- and five-year age-standardized net survival (ASNS) in each deprivation quintile and deprivation 
gap (DG), by cancer site, among men 
 
ASNS: Age-standardized net survival 
DG : Deprivation Gap= ASNSQ1 - ASNSQ5 
CI95% : 95% confidence interval 
* age-standardization was not possible for breast cancer in men due to small sample size 
 
 
Table 4. One- and five-year age-standardized net survival (ASNS) in each deprivation quintile and deprivation 
gap (DG), by cancer site, among women 
 
ASNS: Age-standardized net survival 
DG : Deprivation Gap= ASNSQ1 - ASNSQ5 
CI95% : 95% confidence interval 
 
 
 
 
Table 1. Description of records from the FRANCIM registries used in the study  
  
N 
Inclusi
on 
period 
for 
dates 
of 
diagno
sis 
 Incomplet
e date of 
last 
informati
on 
 Date of 
diagnosis=d
ate of death 
  Lost to 
follow-up 
   N %  N %   N % 
Calvados registry of digestive tumors 3,051 2006-
2009 
 0 0  3 0.1  35 1.1 
Calvados cancer registry 9,385 2006-
2009 
 0 0  3 <0.1  25 0.3 
Côte d’Or/Saône et Loire registry of digestive tumors (data relative to 
Côte d’Or) 
2,401 2006-
2009 
 0 0  2 0.1  17 0.7 
Côte d’Or registry of gynecological tumors 1,552 2006-
2009 
 0 0  0 0  34 2.2 
Doubs cancer registry 9,632 2006-
2009 
 0 0  6 0.1  126 1.3 
Finistère registry of digestive tumors 4,724 2006-
2009 
 14 0.3  11 0.2  83 1.8 
Gironde cancer registry 11,92
4 
2008-
2009 
 30 0.3  6 0.1  579 4.9 
Gironde registry of CNS tumors 385 2006-
2009 
 3 0.8  0 0  13 3.4 
Hérault cancer registry 18,77
5 
2006-
2009 
 0 0  18 0.1  429 2.3 
Isère cancer registry 21,15
2 
2006-
2009 
 0 0  11 0.1  422 2.0 
Loire-Atlantique/Vendée cancer registry (data relative to Loire-
Atlantique) 
23,09
4 
2006-
2009 
 5 <0.
1 
 27 0.1  490 2.1 
Manche cancer registry 9,537 2006-
2009 
 0 0  19 0.2  129 1.4 
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Bas-Rhin cancer registry 19,76
5 
2006-
2009 
 0 0  28 0.1  317 1.6 
Haut-Rhin cancer registry 12,55
8 
2006-
2009 
 1 <0.
1 
 16 0.1  302 2.4 
Côte d’Or/Saône et Loire registry of digestive tumors (data relative to 
Saône et Loire)  
2,808 2006-
2009 
 0 0  6 0.2  39 1.4 
Somme cancer registry 10,41
9 
2006-
2009 
 0 0  26 0.2  352 3.4 
Tarn cancer registry 7,725 2006-
2009 
 0 0  9 0.1  117 1.5 
Loire-Atlantique/Vendée cancer registry (data relative to Vendée) 12,08
7 
2006-
2009 
 1 <0.
1 
 18 0.1  366 3.0 
Haute-Vienne cancer registry 1,929 2009  0 0  0 0  38 2.0 
Lille area cancer registry 6,754 2008-
2009 
 0 0  13 0.2  60 0.9 
Total 189,6
57 
  54 <0.
1 
 222 0.1  3,973 2.1 
 
 
 
 
 
Table 2. Characteristics of the population by cancer site and by sex (FRANCIM registries, cancer cases diagnosed 
between 2006-2009) 
  Men  Women 
 ICD-O-3 
Topography/M
orphology 
N N 
deat
hs 
Me
dian 
follo
w-
up 
time 
(yea
r) 
Me
dian 
age 
(yea
r) 
Deprivation quintile 
(%) 
5-
ye
ar 
AS
NS 
 N N 
deat
hs 
Me
dian 
follo
w-
up 
time 
(yea
r) 
Me
dian 
age 
(yea
r) 
Deprivation quintile 
(%) 
5-
ye
ar 
AS
NS 
Q
1 
Q
2 
Q
3 
Q
4 
Q
5 
 Q
1 
Q
2 
Q
3 
Q
4 
Q
5 
Solid 
tumor 
sites 
                      
Head 
& 
neck 
C00-14 & C30-
32 /all 
8,4
05 
5,17
5 
2.86 60 15
.3 
18
.3 
19
.3 
19
.8 
27
.3 
42.
0 
 1,9
89 
995 3.68 61 14
.2 
17
.2 
20
.4 
21
.8 
26
.4 
52.
0 
Esoph
agus 
C15/all 3,2
50 
2,83
1 
0.91 66 17
.3 
20
.2 
20
.8 
19
.9 
21
.8 
14.
4 
 705 599 0.75 72 14
.8 
19
.9 
19
.4 
24
.4 
21
.6 
15.
7 
Stoma
ch 
C16/all 3,4
93 
2,77
7 
1.00 72 18
.1 
20
.6 
19
.8 
19
.4 
22
.1 
25.
0 
 1,9
05 
1,40
7 
1.00 77 14
.9 
19
.7 
20
.2 
21
.7 
23
.6 
31.
7 
Colon
-
rectu
m 
C18-21/all 16,
339 
8,14
2 
3.82 71 18
.6 
21
.4 
21
.6 
19
.5 
18
.9 
61.
5 
 13,
348 
6,40
6 
3.81 74 17
.3 
20
.4 
20
.6 
20
.2 
21
.5 
63.
5 
Liver C22/all 4,9
79 
4,30
8 
0.77 69 19
.2 
20
.7 
19
.4 
20
.2 
20
.5 
15.
2 
 1,1
15 
956 0.65 74 15
.1 
18
.4 
19
.6 
19
.5 
27
.4 
17.
1 
Bile 
duct 
C23-24/all 848 710 0.92 73 20
.0 
17
.2 
19
.7 
21
.3 
21
.7 
19.
9 
 1,0
11 
873 0.64 77 15
.3 
20
.3 
18
.4 
23
.7 
22
.3 
18.
1 
Pancr
eas 
C25/all 3,4
16 
3,15
5 
0.48 69 19
.3 
20
.1 
21
.2 
18
.7 
20
.7 
8.6  3,1
87 
2,96
2 
0.45 75 15
.9 
19
.2 
20
.6 
21
.4 
22
.8 
8.7 
Lung C33-34/all 16,
248 
13,9
64 
0.79 66 16
.0 
17
.9 
19
.6 
19
.9 
26
.6 
15.
2 
 4,9
64 
4,02
0 
0.95 65 15
.6 
18
.4 
18
.1 
20
.9 
27
.0 
19.
0 
Sarco
ma 
*see footnote 742 366 3.75 62 19
.5 
19
.7 
17
.5 
21
.3 
22
.0 
58.
0 
 549 256 3.85 64 16
.6 
19
.7 
20
.0 
22
.4 
21
.3 
61.
0 
Melan
oma 
C44/87203-
87803 
2,6
94 
636 4.61 62 24
.6 
21
.2 
19
.8 
17
.9 
16
.5 
87.
8 
 3,1
58 
477 4.81 59 22
.8 
20
.7 
20
.1 
18
.6 
17
.7 
91.
8 
Breast C50/all 275 81 4.59 68 20
.7 
18
.9 
25
.1 
17
.1 
18
.2 
80.
4 
 31,
787 
5,45
5 
4.88 61 19
.7 
20
.4 
19
.4 
19
.4 
21
.1 
86.
7 
Cervix 
uteri 
C53/all            1,8
43 
706 4.22 51 14
.2 
18
.6 
17
.9 
19
.5 
29
.8 
61.
6 
Corpu
s uteri 
C54/all            4,1
21 
1,33
0 
4.36 68 18
.3 
19
.5 
19
.9 
19
.5 
22
.8 
74.
2 
Ovary C569-74/all            2,9
66 
1,75
6 
3.27 66 19
.9 
18
.9 
20
.0 
21
.4 
19
.8 
42.
0 
Prosta
te 
C61/all 36,
585 
7,28
4 
4.99 69 20
.9 
21
.0 
20
.2 
19
.2 
18
.6 
92.
4 
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Kidne
y 
C64/all 3,7
04 
1,40
4 
4.28 65 19
.8 
20
.5 
19
.9 
20
.3 
19
.5 
68.
6 
 1,9
33 
659 4.32 69 18
.2 
21
.2 
19
.0 
19
.8 
21
.7 
72.
9 
Bladd
er 
C67/all 5,3
31 
3,12
1 
3.12 73 16
.5 
19
.0 
20
.4 
20
.8 
23
.4 
53.
5 
 1,2
80 
811 1.74 78 16
.1 
17
.6 
18
.9 
21
.8 
25
.6 
49.
4 
Centr
al 
nervo
us 
syste
m 
C70-72/all 1,6
81 
1,37
4 
1.06 61 22
.0 
19
.9 
19
.1 
19
.5 
19
.6 
22.
6 
 1,3
18 
1,02
7 
0.97 65 17
.6 
20
.6 
19
.5 
20
.3 
22
.0 
28.
0 
Thyroi
d 
C739/all 1,0
81 
134 4.88 55 21
.9 
20
.6 
18
.6 
18
.4 
20
.4 
90.
9 
 3,4
07 
161 5.05 51 22
.4 
20
.3 
19
.0 
18
.3 
20
.1 
96.
5 
* 1- Topography codes for sarcoma: C381, C382, C383, C47, C480, C49, C696, C76, C809, morphology codes for sarcoma : 8900-05, 8910, 8912, 8920, 8991, 
8810, 8811, 8813-15, 8821, 8823, 8834-35, 8820, 8822, 8824-27, 9150, 9160, 9491, 9540-971, 9580, 9140, 8587, 8710-13, 8806, 8831-33, 8836, 8840-42, 8850-
58, 8860-62, 8870, 8880, 8881, 8890-98, 8921, 8982, 8990, 9040-44, 9120-25, 9130-33, 9135, 9136, 9141, 9142, 9161, 9170-75, 9231, 9251, 9252, 9373, 9581, 
8830, 8963, 9180, 9210, 9220, 240, 9260, 9364, 9365, 8800-05 
ASNS: age-standardized net survival 
 
 
 
 
Table 3. One- and five-year age-standardized net survival (ASNS) in each deprivation quintile and deprivation 
gap (DG), by cancer site, among men 
 1-year age-standardized net survival 
1-year DG 
[CI95%] 
 5-year age-standardized net survival 
5-year DG 
[CI95%] 
 Q1 (Least 
deprived) 
Q2 Q3 Q4 Q5 (Most 
deprived) 
 Q1 (Least 
deprived) 
Q2 Q3 Q4 Q5 (Most 
deprived) 
Solid tumor 
sites 
             
Head & 
neck 75.7 75.9 70.8 72.1 68.9 6.8 [3.1;10.5] 
 
49.7 45.6 39.6 40.7 38.1 11.6 [6.8;16.5] 
Esophagus 51.1 51.9 47.8 46.0 43.5 7.5 [1.9;13.2]  16.4 15.9 11.7 12.4 16.0 0.4 [-4.2;5.0] 
Stomach 58.8 52.2 54.8 56.5 52.4 6.4 [1.1;11.7]  28.1 22.2 25.1 23.9 26.1 2.0 [-3.3;7.3] 
Colon-
rectum 85.6 84.5 84.7 81.7 82.7 2.9 [1.0;4.8] 
 
64.2 63.7 61.0 60.1 57.9 6.4 [3.3;9.5] 
Liver 49.0 49.5 42.9 48.2 42.2 6.8 [2.1;11.4]  18.4 15.6 16.2 14.5 12.2 6.2 [2.5;10.0] 
Bile duct 55.4 46.4 57.1 51.5 50.2 5.2 [-5.5;15.8]  17.9 20.8 21.1 18.1 21.6 -3.7 [-13.6;6.2] 
Pancreas 36.3 33.4 29.4 31.7 29.5 6.7 [1.7;11.8]  9.9 8.5 7.5 8.7 9.2 0.8 [-2.7;4.2] 
Lung 45.6 44.5 43.2 43.6 43.0 2.6 [-0.1;5.2]  17.2 15.2 15.0 15.4 14.3 2.9 [0.7;5.0] 
Sarcoma 88.2 84.2 81.8 78.9 81.8 6.4 [-1.1;13.9]  58.7 58.1 53.9 59.9 61.0 -2.3 [-14.6;9.9] 
Melanoma 98.9 98.9 95.8 95.8 97.5 1.4 [-0.8;3.7]  92.3 87.8 85.6 84.6 87.3 5.0 [-0.5;10.6] 
Breast* 100.0 97.5 95.6 98.2 94.9 5.2 [-3.3;13.6]  89.3 74.4 87.5 76.6 71.1 18.2 [-2.7;39.2] 
Prostate 98.2 98.3 97.9 97.5 97.7 0.5 [-0.3;1.3]  93.8 93.1 91.8 91.7 90.7 3.0 [1.1;5.0] 
Kidney 85.8 86.0 82.4 81.2 81.7 4.2 [0.0;8.4]  72.2 71.0 65.9 67.0 67.2 5.0 [-1.2;11.3] 
Bladder 81.7 81.2 78.5 77.9 76.9 4.8 [0.8;8.7]  57.7 55.6 53.7 50.1 51.2 6.4 [0.9;12.0] 
Central 
nervous 
system 58.4 62.8 56.4 54.5 55.1 3.2 [-3.8;10.2] 
 
23.9 20.6 21.9 22.9 23.2 0.6 [-5.7;6.9] 
Thyroid 95.6 93.3 95.3 95.5 96.6 -1.1 [-5.7;3.6]  98.0 86.8 88.5 90.6 90.9 7.1 [-0.6;14.8] 
ASNS: Age-standardized net survival 
DG : Deprivation Gap= ASNSQ1 - ASNSQ5 
CI95% : 95% confidence interval 
* age-standardization was not possible for breast cancer in men due to small sample size 
 
 
 
Table 4. One- and five-year age-standardized net survival (ASNS) in each deprivation quintile and deprivation 
gap (DG), by cancer site, among women 
 1-year age-standardized net survival 
1-year DG 
[CI95%] 
 5-year age-standardized net survival 
5-year DG 
[CI95%] 
 Q1 (Least 
deprived) 
Q2 Q3 Q4 Q5 (Most 
deprived) 
 Q1 (Least 
deprived) 
Q2 Q3 Q4 Q5 (Most 
deprived) 
Solid tumor 
sites 
             
Head & 
neck 77.0 76.5 79.4 77.7 73.1 3.9 [-2.9;10.7] 
 
56.4 56.8 55.0 55.1 41.6 14.9 [6.2;23.5] 
Esophagus 56.4 41.8 45.1 43.5 40.8 15.7 [3.3;28.1]  23.0 20.2 10.9 13.8 10.9 12.1 [1.9;22.4] 
Stomach 61.9 53.8 59.6 59.9 57.6 4.3 [-3.5;12.0]  31.4 30.3 31.8 35.0 30.7 0.8 [-7.4;8.9] 
Colon-
rectum 85.9 85.0 83.6 83.5 82.0 3.9 [1.9;6.0] 
 
66.0 64.0 63.4 63.7 60.6 5.5 [2.2;8.7] 
Liver 48.9 48.7 50.1 44.2 42.0 6.9 [-2.9;16.7]  17.3 21.0 16.9 18.7 13.9 3.4 [-4.4;11.1] 
Bile duct 49.4 53.6 51.6 42.0 40.0 9.3 [-1.3;19.9]  23.1 22.7 22.9 16.5 9.5 13.6 [4.0;23.3] 
Pancreas 37.5 35.2 33.8 35.1 30.2 7.2 [1.6;12.8]  11.7 7.4 6.2 10.1 8.4 3.4 [-0.6;7.4] 
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Lung 51.9 51.1 48.5 47.4 49.0 2.9 [-1.6;7.4]  20.9 20.8 18.3 19.1 17.3 3.6 [-0.2;7.4] 
Sarcoma 76.4 85.3 91.1 84.5 82.1 -5.7 [-16.4;4.9]  57.4 61.2 72.1 57.0 59.3 -1.9 [-15.6;11.8] 
Melanoma 98.9 98.6 99.2 98.7 98.1 0.8 [-1.0;2.6]  92.9 94.4 90.4 91.6 89.8 3.1 [-1.3;7.4] 
Breast 97.6 97.2 97.0 96.5 96.0 1.6 [0.6;2.5]  88.8 87.6 87.3 86.3 83.7 5.1 [2.9;7.3] 
Cervix uteri 88.0 88.2 85.9 86.9 87.2 0.8 [-4.8;6.4]  68.2 64.4 61.2 62.6 56.9 11.3 [3.4;19.3] 
Corpus 
uteri 91.8 90.6 90.3 88.7 88.3 3.5 [0.5;6.5] 
 
77.7 75.5 73.6 72.3 72.8 4.9 [-0.2;9.9] 
Ovary 79.1 78.3 74.7 75.4 75.4 3.8 [-1.0;8.6]  41.7 46.1 40.5 40.6 40.8 1.0 [-5.1;7.0] 
Kidney 89.4 85.2 84.6 83.0 85.4 4 [-0.8;8.8]  77.0 74.0 68.9 70.9 73.3 3.6 [-3.6;10.9] 
Bladder 77.4 70.9 69.9 71.9 67.9 9.5 [1.3;17.8]  54.2 45.6 53.4 50.3 45.3 8.9 [-2.0;19.8] 
Central 
nervous 
system 57.9 63.4 57.3 56.4 56.2 1.6 [-6.1;9.4] 
 
25.1 31.8 29.2 26.8 27.5 -2.4 [-10.4;5.6] 
Thyroid 96.2 97.5 98.0 96.7 97.3 -1.2 [-4.1;1.7]  97.4 96.2 96.5 96.6 96.5 0.9 [-3.2;4.9] 
ASNS: Age-standardized net survival 
DG : Deprivation Gap= ASNSQ1 - ASNSQ5 
CI95% : 95% confidence interval 
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Figures Legends 
 
 
Figure 1. Variation of 1- and 5-year age-standardized net survival (ASNS) between the least (Q1) and the most 
(Q5) deprived quintile, by cancer site, among men 
 
ASNS: Age-standardized net survival 
* age-standardization was not possible for breast cancer in men due to small sample size 
 
 
Figure 2. Variation of 1- and 5-year age-standardized net survival (ASNS) between the least (Q1) and the most 
(Q5) deprived quintile, by cancer site, among women 
 
ASNS: Age-standardized net survival 
 
Supplementary figure 1. Map of the French Network of Cancer Registries coverage and the study population 
coverage. 
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Appendix 
 
Members of the French Network of Cancer Registries (FRANCIM): Françoise GALATEAU-SALLE 
(Registre multicentrique du mésothéliome à vocation nationale (Mesonat)), Anne-Marie BOUVIER 
(Registre Bourguignon des cancers digestifs), Simona BARA (Registre des cancers de la Manche), 
Clarisse JOACHIM-CONTARET (Registre des cancers de la Martinique), Olivier GANRY (Registre 
général des cancers de la Somme), Claire SCHVARTZ (Registre des cancers de la thyroïde Marne 
Ardennes), Sandrine PLOUVIER (Registre des cancers de Lille et de sa region), Guy LAUNOY (Registre 
des cancers digestifs du Calvados), Emilie MARRER (Registre des cancers du Haut-Rhin), Patrick 
ARVEUX (Registre des cancers du sein et des cancers gynécologiques de Côte d'Or), Pascale 
GROSCLAUDE (Registre des cancers généraux du Tarn), Xavier TROUSSARD (Registre des 
hémopathies malignes de Basse-Normandie), Marc MAYNADIE (Registre des hémopathies malignes 
de Côte d'Or), Alain  MONNEREAU (Registre des hémopathies malignes de la Gironde), Jean Pierre 
DAURES (Registre général des tumeurs de l'Hérault), Florence MOLINIE (Registre des tumeurs de 
Loire-Atlantique/Vendée), Anne-Sophie WORONOFF (Registre des tumeurs du Doubs et du Territoire 
de Belfort), Isabelle BALDI (Registre des tumeurs primitives du système nerveux en Gironde), Jean-
Baptiste NOUSBBAUM (Registre Finistérien des tumeurs digestives), Gaëlle COUREAU (Registre 
général des cancers de la Gironde), Jacqueline DELOUMEAUX (Registre général des cancers de la 
Guadeloupe), Marc COLONNA (Registre général des cancers de l'Isère), Michel VELTEN (Registre 
général des cancers du Bas-Rhin), Tania D'ALMEIDA (Registre général des cancers en région 
Limousin), Anne-Valérie GUIZARD (Registre général des tumeurs du Calvados), Jacqueline CLAVEL 
(Registre national des hémopathies malignes de l'enfant (RNHME)), Brigitte LACOUR (Registre 
national des tumeurs solides de l'enfant (RNTSE)), Borson-Chazot (Registre Rhône Alpin des cancers 
thyroïdiens), Pierre INGRAND (Registre des cancers de Poitou-Charentes), Sylvie Laumod (Cancers 
généraux - Nouvelle Calédonie), Emmanuel CHIRPAZ (Registre des Cancers de la Réunion), Laure-
Manuella DESROZIERS-IMOUNGA (Registre des cancers généraux de Guyane). 
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